OTCMKTS:RSPI Cortex Pharmaceuticals (RSPI) Stock Price, News & Analysis $0.0015 +0.00 (+114.29%) As of 03:34 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About Cortex Pharmaceuticals Stock (OTCMKTS:RSPI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cortex Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0015▼$0.001550-Day Range N/A52-Week Range$0.0001▼$0.0027Volume12,000 shsAverage Volume491,208 shsMarket Capitalization$1.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cortex Pharmaceuticals, Inc. (OTCMKTS: RSPI) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system (CNS) disorders. The company’s drug discovery efforts center on positive allosteric modulators of AMPA receptors, which have the potential to enhance synaptic transmission and support cognitive function. Cortex’s lead candidate, CX-717, has been studied for applications in attention deficit hyperactivity disorder, respiratory stimulation, and age-related memory decline. The company’s research platform integrates medicinal chemistry, pharmacology and translational neuroscience to advance compounds through preclinical and clinical development. Over its history, Cortex Pharmaceuticals has established strategic collaborations with academic research centers and contract research organizations to accelerate the clinical evaluation of its pipeline candidates. In addition to its U.S. headquarters in Irvine, California, the company maintains relationships with European research sites to support multi‐center clinical trials. Cortex has also engaged in partnerships to explore combination therapies and formulation improvements aimed at optimizing delivery and patient compliance. Through these alliances, Cortex seeks to expand the potential therapeutic applications of its proprietary modulators. Founded in 1996, Cortex Pharmaceuticals has navigated the challenges of early-stage drug development by leveraging a focused scientific approach and opportunistic licensing agreements. The company’s executive team brings together seasoned professionals with experience in neuroscience, regulatory affairs and pharmaceutical operations. Cortex’s leadership is supported by a board of directors and scientific advisors with deep expertise in CNS pharmacology and commercial strategy. Together, they are committed to advancing the company’s clinical programs and delivering potential treatment options for patients with cognitive and neurological disorders.AI Generated. May Contain Errors. Read More Receive RSPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cortex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RSPI Stock News HeadlinesRespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, ...February 10, 2025 | gurufocus.comRespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord InjuryMay 29, 2024 | globenewswire.comI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.July 18 at 2:00 AM | Timothy Sykes (Ad)RespireRx Pharmaceuticals Inc (RSPI)May 23, 2024 | investing.comRespireRx Pharmaceuticals Inc RSPIMay 1, 2024 | morningstar.comMRCKT Rocket Pharmaceuticals, Inc.April 20, 2024 | seekingalpha.comRespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord InjuryMarch 20, 2024 | globenewswire.comRespireRx Pharmaceuticals shares Preclinical Pain Relief for their Non-Opioid Lead KRM-II-81March 9, 2024 | proactiveinvestors.comSee More Headlines RSPI Stock Analysis - Frequently Asked Questions How have RSPI shares performed this year? Cortex Pharmaceuticals' stock was trading at $0.0008 on January 1st, 2025. Since then, RSPI shares have increased by 87.5% and is now trading at $0.0015. How were Cortex Pharmaceuticals' earnings last quarter? Cortex Pharmaceuticals Inc. (OTCMKTS:RSPI) posted its quarterly earnings results on Wednesday, August, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter. How do I buy shares of Cortex Pharmaceuticals? Shares of RSPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cortex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cortex Pharmaceuticals investors own include American Bio Medica (ABMC), Galaxy Next Generation (GAXY), Asia Broadband (AABB), Aquestive Therapeutics (AQST), Appian (APPN), Arista Networks (ANET) and AMC Entertainment (AMC). Company Calendar Last Earnings8/19/2020Today7/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:RSPI CIK849636 Webwww.respirerx.com Phone(201) 444-4947Fax949-727-3657Employees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares949,460,000Free Float474,447,000Market Cap$1.42 million OptionableNot Optionable Beta0.14 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (OTCMKTS:RSPI) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortex Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.